Maternal and feto-placental prostanoid responses to a single course of antenatal betamethasone

Prostaglandins Other Lipid Mediat. 2005 Dec;78(1-4):139-59. doi: 10.1016/j.prostaglandins.2005.06.003. Epub 2005 Jul 21.

Abstract

We tested the hypothesis that antenatal betamethasone alters prostanoid levels in the maternal and feto-placental compartments. Forty-three singleton pregnancies were studied. Group I were women treated with a single course of antenatal betamethasone and who delivered <37 weeks gestation; Group II were untreated women who delivered <37 weeks; and Group III were untreated women who delivered >38 weeks. Maternal and mixed cord blood; and placental samples were collected at delivery and analyzed for PGE2, PGF(2alpha), 6-ketoPGF(1alpha), and TxB2 levels. Antenatal betamethasone decreased maternal PGE2 levels with concomitant increases in the feto-placental compartment. Umbilical cord TxB2 levels in the treated group were significantly lower than the non-treated pre-term and term groups resulting in a higher 6-ketoPGF(1alpha):TxB2 ratio. Considering the regulatory role of PGE2 and PGI2 in fetal lung development and neonatal transition homeostasis, these results suggest a mechanism, at least in part, for the beneficial effects of antenatal steroids on fetal lung maturation and neonatal cardio-pulmonary homeostasis at birth.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Betamethasone / administration & dosage
  • Betamethasone / pharmacology*
  • Female
  • Fetus / drug effects*
  • Humans
  • Infant, Newborn
  • Maternal-Fetal Exchange
  • Pilot Projects
  • Placenta / drug effects*
  • Pregnancy
  • Prostaglandins / metabolism
  • Respiratory Distress Syndrome, Newborn / prevention & control

Substances

  • Prostaglandins
  • Betamethasone